Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badania przesiewowe w kierunku raka płuc u starszych pacjentów (badanie przesiewowe PLCO)

17 listopada 2026 zaktualizowane przez: National Cancer Institute (NCI)

Próba przesiewowa raka prostaty, płuc, jelita grubego i jajnika (PLCO).

This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for lung cancer.

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Szczegółowy opis

PRIMARY OBJECTIVES:

I. To determine whether screening with chest x-ray can reduce mortality from lung cancer in women and men aged 55-74 at entry.

SECONDARY OBJECTIVES:

I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.

II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.

IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.

OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).

ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.

ARM II (Lung Screening): Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as "smokers" undergo an additional chest x-ray at year 3. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal lung cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with lung cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.

Participants complete a Baseline Questionnaire (BQF/M) to assess smoking status. Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial.

After completion of screening, participants are followed up for at least 13 years.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

154901

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Maryland
      • Bethesda, Maryland, Stany Zjednoczone, 20892
        • National Institutes of Health Clinical Center

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

55 lat do 74 lata (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Exclusion Criteria:

  • Men and women who at the time of randomization are less than 55 or greater than or equal to 75 years of age

  • Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer

  • Individuals with known prior cancer of the colon, rectum, lung, prostate (men only) or ovary (women only)

    • This includes primary or metastatic PLCO cancers
  • Individuals with previous surgical removal of the entire colon, one lung, or the entire prostate (men only)

    • Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
  • Individuals who are participating in another cancer screening or cancer primary prevention trial

  • Males who have taken Proscar/Propecia/finasteride in the past 6 months

    • NOTE: Individuals who are already enrolled in the trial when their physician prescribes finasteride are not prevented from taking this medication. As a result, these participants will continue to be screened and followed just as those participants who are not on finasteride.
    • NOTE: Men who are taking Tamoxifen are not excluded from any part of the PLCO Screening Trial.
    • Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\Raloxifene are not excluded from participation.
  • Individuals who are unwilling or unable to sign the informed consent form

  • Males who have had more than one PSA blood test in the past three years

  • Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Ekranizacja
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Brak interwencji: Control

Participants receive standard medical care. Participants complete a DHQ at baseline.

Aktywny komparator: Lung Screening

Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as "smokers" undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial.

Undergo questionnaire assessments

Undergo a chest x-ray

Inne nazwy:
  • Konwencjonalne promieniowanie rentgenowskie
  • Radiologia diagnostyczna
  • Obrazowanie medyczne, rentgen
  • Obrazowanie radiograficzne
  • Radiografia
  • RG
  • Statyczne promieniowanie rentgenowskie
  • Rentgenowskie
  • Zwykłe zdjęcia rentgenowskie
  • Procedura obrazowania radiograficznego (zabieg)

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Lung Cancer Deaths
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Lung cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Lung Cancer Death Rates
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Lung cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Deaths From All Causes
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Deaths from all causes were compared between the lung screening arm and the usual care arm.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Death Rates From All Causes
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Deaths from all causes were compared between the lung screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Lung Cancer Incidence
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Lung cancer diagnoses confirmed by medical record abstraction.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Lung Cancer Incidence Rates
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Lung cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as lung cancer diagnoses divided by person years at risk for lung cancer.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Complications of Diagnostic Evaluation Following a Positive Screening Test
Ramy czasowe: One year from screening examination

Number of positive screens with complications.

One year from screening examination
T0 (Baseline) CXR Screening Results
Ramy czasowe: T0 (at study entry)

Postero-anterior view chest radiograph (CXR) result

T0 (at study entry)
T1 CXR Screening Results
Ramy czasowe: T1 (one year after entry)

Postero-anterior view chest radiograph (CXR) result

T1 (one year after entry)
T2 CXR Screening Results
Ramy czasowe: T2 (two years after entry)

Postero-anterior view chest radiograph (CXR) result

T2 (two years after entry)
T3 CXR Screening Results
Ramy czasowe: T3 (three years after entry)

Postero-anterior view chest radiograph (CXR) result

T3 (three years after entry)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Christine D Berg, National Cancer Institute (NCI)

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

16 listopada 1993

Zakończenie podstawowe (Rzeczywisty)

21 maja 2012

Ukończenie studiów (Szacowany)

30 czerwca 2027

Daty rejestracji na studia

Pierwszy przesłany

28 września 2012

Pierwszy przesłany, który spełnia kryteria kontroli jakości

1 października 2012

Pierwszy wysłany (Szacowany)

2 października 2012

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

18 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

17 listopada 2026

Ostatnia weryfikacja

1 lipca 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • NCI-2012-01756
  • NCI-2012-01756 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
  • CDR0000078532
  • NCI-P93-0050
  • PLCO-1
  • PLCO-Lung (Inny identyfikator: National Cancer Institute)

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj